Jacob Aelion

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 652 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +4

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 496 citations

Medicine, Pharmacology, Pharmacotherapy +12

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis.

Donald Y.M. Leung, Jeffrey B. Travers, Ralph Giorno et al. · Journal of Clinical Investigation · 1995 · 298 citations · Full text

Life Sciences, Immunology, Pathology +17

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · Annals of the Rheumatic Diseases · 2012 · 288 citations

Life Sciences, Immunology, Pharmacotherapy +17

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases · 2016 · 283 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15